Literature DB >> 18727068

The use of receiver operating characteristic analysis for detection of minimal residual disease using five-color multiparameter flow cytometry in acute myeloid leukemia identifies patients with high risk of relapse.

Adhra Al-Mawali1, David Gillis, Ian Lewis.   

Abstract

BACKGROUND: Multiparameter flow cytometry (MFC) has been shown to be a useful approach for detection of minimal residual disease (MRD). The aim of the study was to determine the optimal threshold that can separate patients into two groups in terms of leukemic residual cells and relapse status after induction and consolidation chemotherapy.
METHODS: Five-color MFC and receiver operating characteristics (ROC) analysis were used to determine the optimal threshold. This study analyzed 54 acute myeloid leukemia (AML) patients.
RESULTS: LAPs were detected in 51/54 (94%) patients. MRD was evaluated in the bone marrow (BM) in morphologic complete remission from 25 and 22 patients after induction and consolidation, respectively. The threshold discriminating MRD(-) from MRD(+) cases was set at 0.15% residual leukemic cells, a level that allowed optimal sensitivity and specificity for prediction of relapse, both at postinduction (P = 0.05) and postconsolidation (P = 0.009) time points using ROC analysis. MRD level postinduction not only influenced relapse-free survival (RFS) (P = 0.004) but also overall survival (OS) (P = 0.003). Multivariate analysis showed that MRD level postinduction was a powerful independent prognostic factor for both RFS (P = 0.037) and OS (P = 0.026).
CONCLUSIONS: Using the ROC analysis, the threshold of 0.15% was defined as the optimal value in discriminating risk categories in AML, and postinduction MRD assessment is able to better predict disease outcome than consolidation. Therefore, MRD analysis by MFC could be used for refining the selection of therapeutic strategies and improving clinical outcome in individual patients. 2008 Clinical Cytometry Society.

Entities:  

Mesh:

Year:  2009        PMID: 18727068     DOI: 10.1002/cyto.b.20444

Source DB:  PubMed          Journal:  Cytometry B Clin Cytom        ISSN: 1552-4949            Impact factor:   3.058


  10 in total

Review 1.  Multi-color flow cytometric immunophenotyping for detection of minimal residual disease in AML: past, present and future.

Authors:  J M Jaso; S A Wang; J L Jorgensen; P Lin
Journal:  Bone Marrow Transplant       Date:  2014-05-19       Impact factor: 5.483

Review 2.  Minimal/Measurable Residual Disease Detection in Acute Leukemias by Multiparameter Flow Cytometry.

Authors:  Franklin Fuda; Weina Chen
Journal:  Curr Hematol Malig Rep       Date:  2018-12       Impact factor: 3.952

3.  Peripheral blood minimal residual disease may replace bone marrow minimal residual disease as an immunophenotypic biomarker for impending relapse in acute myeloid leukemia.

Authors:  W Zeijlemaker; A Kelder; Y J M Oussoren-Brockhoff; W J Scholten; A N Snel; D Veldhuizen; J Cloos; G J Ossenkoppele; G J Schuurhuis
Journal:  Leukemia       Date:  2015-09-16       Impact factor: 11.528

Review 4.  Minimal residual disease quantitation in acute myeloid leukemia.

Authors:  David Shook; Elaine Coustan-Smith; Raul C Ribeiro; Jeffrey E Rubnitz; Dario Campana
Journal:  Clin Lymphoma Myeloma       Date:  2009

5.  Clinical analysis and optimization of postremission therapy for acute myeloid leukemia patients with minimal residual disease as determined by flow cytometry.

Authors:  Daichi Inoue; Hayato Maruoka; Takayuki Takahashi
Journal:  Mediterr J Hematol Infect Dis       Date:  2010-08-05       Impact factor: 2.576

Review 6.  Minimal Residual Disease in Acute Myeloid Leukemia of Adults: Determination, Prognostic Impact and Clinical Applications.

Authors:  Maria Ilaria Del Principe; Francesco Buccisano; Luca Maurillo; Giuseppe Sconocchia; Mariagiovanna Cefalo; Maria Irno Consalvo; Chiara Sarlo; Consuelo Conti; Giovanna De Santis; Eleonora De Bellis; Ambra Di Veroli; Patrizia Palomba; Cristina Attrotto; Annagiulia Zizzari; Giovangiacinto Paterno; Maria Teresa Voso; Giovanni Del Poeta; Francesco Lo-Coco; William Arcese; Sergio Amadori; Adriano Venditti
Journal:  Mediterr J Hematol Infect Dis       Date:  2016-10-20       Impact factor: 2.576

7.  Combined usage of Wilms' tumor gene quantitative analysis and multiparameter flow cytometry for minimal residual disease monitoring of acute myeloid leukemia patients after allogeneic hematopoietic stem cells transplantation.

Authors:  Yingchan Hao; Yanhong Cheng; Quan Wu; Aimei Zhang; Xiaoxiao Jiang; Xiucai Xu
Journal:  Exp Ther Med       Date:  2017-11-23       Impact factor: 2.447

8.  Measurable Residual Disease Detected by Multiparameter Flow Cytometry and Sequencing Improves Prediction of Relapse and Survival in Acute Myeloid Leukemia.

Authors:  Fu-Jia Liu; Wen-Yan Cheng; Xiao-Jing Lin; Shi-Yang Wang; Tian-Yi Jiang; Ting-Ting Ma; Yong-Mei Zhu; Yang Shen
Journal:  Front Oncol       Date:  2021-05-20       Impact factor: 6.244

9.  Immunoprofiling of leukemic stem cells CD34+/CD38-/CD123+ delineate FLT3/ITD-positive clones.

Authors:  Adhra Al-Mawali; David Gillis; Ian Lewis
Journal:  J Hematol Oncol       Date:  2016-07-27       Impact factor: 17.388

10.  Survival outcomes of CD34+CD38-LSCs and their expression of CD123 in adult AML patients.

Authors:  Asmaa M Zahran; Sanaa Shaker Aly; Amal Rayan; Omnia El-Badawy; Maged Abdel Fattah; Arwa Mohammed Ali; Hala M ElBadre; Helal F Hetta
Journal:  Oncotarget       Date:  2018-09-25
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.